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ABSTRACT 
Cry1Ab is a member of the family of crystal (Cry) toxins, produced by a soil bacterium Bacillus 
thuringiensis, and used globally as a commercial pesticide. A thorough knowledge of the 
mechanism by which the toxin acts is essential for preventing possible pest resistance to the 
toxin. While the upstream steps of the mechanism, including activation of the toxin in the 
alkaline midgut of the target lepidopteran insect followed by binding to its receptors are well 
understood, the final step of insertion of the toxin into insect brush border membranes remains 
controversial. The Umbrella and Penknife models hypothesize that the toxin partitions into the 
apical membrane of the insect midgut by insertion of only two –helices from domain I of the 
protein, -helices 4 and 5 in the case of the Umbrella Model and -helices 5 and 6 in the case of 
the Penknife Model. Neither model envisages membrane partitioning by domains II and III. In 
this study, we present data suggesting that mutations in domain II residue, F371 affect insertion 
of the whole toxin into Manduca sexta brush border membrane vesicles (BBMV). 
 
INTRODUCTION 
Insecticidal crystal proteins (Cry toxins) produced by the soil bacterium Bacillus 
thuringiensis are a large family of toxins that target a wide range of insects and nematodes but 
are harmless to mammals (1).  The crystal toxins belonging to the Cry1A series target the insect 
order Lepidoptera. They are produced as inactive protoxins and are activated inside the alkaline 
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lepidopteran gut by proteases. Crystal structures of the active toxin in solution (2, 3) have shown 
that the toxin has 3 structural domains. Domain I is an -helical bundle made of 7 -helices.  
Domain II is predominantly composed of anti-parallel beta sheets, with predominant loops at the 
apex.  Domain III is a - sandwich. The active form binds to one or more receptors on the brush 
border membrane vesicles (BBMV) of the insect, including cadherins, alkaline phosphatases 
and/or one or more forms of the aminopeptidases (4-6). The receptor bound toxin then is 
proposed to undergo several conformational changes such as aggregation and oligomer 
formation (7, 8) before inserting into the membrane. 
Initial models of insertion of toxin into the membrane, the umbrella and penknife models, 
suggest that only -helix 4 and 5 of domain I, in the case of the umbrella model, and -helices 5 
and 6 in the case of the penknife model, insert to form an ion channel (9-11). However there is 
no conclusive evidence presented on the fate of domain II and domain III, which account for 
60% of the bulk of the toxin, upon insertion. Studies using non-specific proteases on Cry toxins 
that have been inserted into the BBMV show that almost the entire toxin of 60 kDa is protected 
inside the membrane (12-15); only -helix 1 is lost from the active toxin in the membrane-bound 
state.  
Site-directed mutagenesis studies involving replacement of single amino acids in domain 
II of Cry1Ab toxin (16, 17) show that mutations in phenylalanine 371 residue to several residues 
including cysteine, serine, alanine, valine, tyrosine and phenylalanine do not affect the 
competition binding of the toxin to BBMV, but there was a significant loss of toxicity that is 
inversely correlated to the hydrophobicity of the replaced residues. This could have been due to 
the hydrophobic residue playing a role in tighter binding of the toxin to BBMV or due to the 
regions of domain II including loop 2 being inserted into the apical membrane of the gut. The 
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Table 1: Bioassay measurements of Cry1Ab and its mutants on 1
st 
instar larvae of M. sexta  
(tobacco hornworms) using surface contamination method. Eight larvae were used per 
concentration of toxin. The results were measured after 5 days of incubation and calculated 
as LC50 using Probit analysis (Softtox).  
present study presents evidence supporting the latter model of domain II inserting into the 
membrane.  
RESULTS 
Production of stable toxins: The desired cysteine and alanine mutations were obtained as 
described in methods and were verified using DNA sequencing. The wild type and mutant 
proteins were expressed in E. coli DH5 as 130 kDa protoxin molecules. All four proteins used 
in this study were digested with trypsin to yield 65 kDa toxin molecules. The protoxin and toxin 
molecule sizes were verified on an 8% SDS –PAGE gel (data not shown).  The trypsin activated 
mutant toxins displayed the same stability as the wild type activated toxin. All activated toxins 
were purified through an ion exchange and 2 gel filtration columns as a monomer of 65 kDa. The 
secondary structures of the purified mutants were compared to that of the wild type Cry1Ab 
using CD spectrometry (data not shown). 
Toxicity Bioassays:  The biological activity of each toxin was measured using surface 
contamination method against M. sexta larvae and the results reported as LC50 (concentration 
required to kill 50% of the larva tested) as shown in Table 1.  
 
Sample LC50 M. sexta (ng/cm
2
) 
Cry1Ab 20.00 
[7.5-31.7] 
1AbV171C 40.3 
[26.6-53.4] 
1AbF371C >2000 
1AbV171C/F371A >2000 
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Surface plasmon resonance analysis: The binding of the mutant toxins to the toxin binding 
cadherin repeats 11 and 12 in the BT-R1 sequence was compared to that of Cry1Ab wild type 
toxin. Table 2 shows that compared to the wild type (KD ~ 18 nM), the 1AbF371C (KD ~ 48nM) 
and the double mutant 1AbF371A/V171C (KD ~ 66 nM) have only a minor decrease in binding.  
 
Sample ka (1/Ms) kd (1/s) KD (M) 
2 
1Abwt:                  exp1 6.51E+04 1.17E-03 1.79E-08 1.08 
                              exp 2 6.42E+04 1.21E—03 1.89E-08 0.859 
1AbV171C:           exp1 7.64E+04 1.84E-03 2.41E-08 6.02 
                              exp 2 7.04E+04 1.55E-03 2.21E-08 1.1 
1AbF371C:            exp1 3.66E+04 1.79E-03 4.89E-08 5.38 
                                exp 2  3.83E+04 1.83E-03 4.78E-08 6.32 
1AbF371A/V171C: exp 1  1.83E+04 1.25E-03 6.80E-08 6.58 
                                exp 2  1.83E+04 1.17E-03 6.41E-08 2.15 
 
Proteinase K protection assays: Protection assays were carried out on toxin bound BBMV to 
determine if each of our toxins inserted into the BBMV. Western blot analysis show that while 
the wild type and the toxic mutant 1AbV171C were protected from 10 fold excess of proteinase 
K even after 30 min of incubation at 37
o 
C, seen as a 60 kDa band on the gel, the domain II 
mutant 1AbF371C and the double mutant 1AbV171C/F371A were completely digested by the 
non-specific protease in the same conditions (Figure 1). The results suggest that the change in 
Table 2: Binding measurements of the toxin 1Abwt and its mutants to cadherin repeats 11 
and 12 using surface plasmon resonance analysis (Biacore). The results are expressed as KD 
values (ratio of the kd:ka) and are expressed in Molar units. Sets of measurements for each 
sample were performed twice, as shown 
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residue F371 to cysteine has an affect on the insertion process. We have observed that F371A 
alone has the same affect (not shown).  
 
 
 
 
 
Fluorescence measurements: The fluorescence emission of acrylodan is highly sensitive to the 
environment of the fluorophore, with the fluorescence maxima of > 480 nm in a hydrophilic 
environment and < 460 nm in a hydrophobic environment (24, 25).  Our studies with the label 
show that while the excited state emission of the acrylodan bound to the protein is very low in 
solution there is a dramatic blue shift in fluorescence emission when the labeled protein is in 
either artificial SUVs or in BBMVs. The dipole moment of the label being highly sensitive to the 
environment, the emission of each labeled mutant is different in the free form itself depending on 
the location of the mutation (24). While a blue shift is the predominant indication of the change 
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Figure 1:  Proteinase K protection assay of Cry1Ab wt and its mutants. Reaction was run on 4-
20% SDS-PAGE gels and the membranes were blotted using anti-1A polyclonal antibody and 
HRP tagged anti rabbit secondary antibody. Lane1: Pure Cry1Abwt (10g). Lane 2: 
proteinase K treated BBMV bound to Cry1Ab wt. Lane 3: Pure 1AbV171C (10g). Lane 4: 
proteinase K treated BBMV bound to 1AbV171C. Lane 5: Pure 1AbF371C (10g). Lane 6: 
proteinase K treated BBMV bound to 1AbF371C. Lane 7: Pure 1AbF371A/V171C (10g). 
Lane 8: proteinase K treated BBMV bound to 1AbF371A/V171C. 
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in the environment, the intensity of the emission is also a representation of the environment of 
the label (25).  
The acrylodan-labeled toxic mutant protein, 1AbV171C shows a blue shift in maximal 
emission wavelength from 500  10 nm in free solution to 462   nm in BBMV and to about the 
same value (462  11 nm) in BBMV treated with proteinase K (Figure 2A). Table 3 records the 
maximal wavelengths for each mutant bound to either SUV or BBMV before and after 
proteinase K treatment.  That the shift was not from hydrophobic effects of the receptors outside  
the vesicles was ensured by the emission spectra from the proteinase K treated BBMV or SUV 
bearing the labeled toxin, since receptors are not present in the case of SUV, and are removed 
from BBMV by proteinase K. The intensity of emission of the spectra both before and after 
proteinase K treatment was similar for this mutant suggesting that the particular region of the 
toxin was embedded into the vesicles.  The acrylodan-labeled domain II mutant, 1AbF371C 
mixed with vesicles (both BBMV and SUV) showed blue shift in the spectra, but upon 
proteinase K treatment, showed a significant drop in fluorescence intensity (Figure 2C and 2F).  
  
 
 
Table 3A 
 
 
 
Maximal emission wavelength of acrylodan labeled 
protein (nm) 
In carbonate buffer Bound to BBMV Bound to BBMV+PK 
1AbV171C 
(Fig 2A) 
500 10 462 9 462 11 
1AbV171C/F371A 
(Fig 2B) 
486 0.5 465 15 458 5 
1AbF371C 
(Fig 2C) 
484 1 482 2 497 2 
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Figure 2: Steady state fluorescence spectra of Cry1Ab mutants labeled with acrylodan. The 
samples were excited at 360 nm and the resultant emission recorded from 390 nm to 650 
nm. The relative fluorescence (Y-axis) is expressed in arbitrary units. Correction of the 
spectra was made against either a buffer blank for the free protein in solution or against 
SUV or BBMV for the protein bound to the respective vesicles. (
________
) represents the 
spectra of the purified labeled protein in solution. (
………….
) represents the spectra of the 
pure labeled protein bound to SUV or BBMV before proteinase K treatment. (----------) 
represents the spectra of labeled protein bound to BBMV or SUV after proteinase K 
treatment. Figure 2A: Cry1AbV171C treated with BBMV. Figure 2B: 
Cry1AbF371A/V171C treated with BBMV. Figure 2C: Cry1AbF371C treated with 
BBMV. Figure 2D: Cry1AbV171C treated with SUV. Figure 2E: Cry1AbF371A/V171C 
treated with SUV. Figure 2F: Cry1AbF371C treated with SUV 
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However for the double mutant (Figure 2E), where the protein was labeled with acrylodan in 
domain I (position 171), the protein was able to insert into the SUVs and was also protected from 
proteinase K in these artificial vesicles as seen by protection of the label in the protease treated 
vesicles. However, upon proteinase K treatment of the toxin bound to BBMV (Figure 2B), there 
was a loss of fluorescence intensity. 
Voltage clamping analysis: To confirm the lack of pore formation of the non –inserting mutants, 
we carried out voltage clamping of M sexta guts and measured the percentage of remaining short 
circuit current in the gut upon addition of Cry1Ab and its mutant proteins used in this study. The 
results as shown in Figure 3 demonstrate that while the domain I mutant V171C can form ion 
channels better than Cry1Ab wild type, the domain II mutant and the double mutant proteins 
have completely lost their ability to form pores in the midgut membrane.  
 
Table 3B 
 
 
Maximal emission wavelength of acrylodan labeled 
protein (nm) 
In carbonate buffer Bound to SUV Bound to SUV+PK 
1AbV171C 
(Fig 2D) 
493 2 475 3 470 6 
1AbV171C/F371A 
(Fig 2E) 
492 1 472 0 480 3 
1AbF371C 
(Fig 2F) 
492 0 466 5 474 1 
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DISCUSSION 
 Rajamohan, et.al  (17) reported that mutating residue F371 to a number of amino acids 
did not affect its competition binding to M. sexta BBMV, but affected toxicity and “irreversible 
binding” in a manner inversely related to the hydrophobicity of the replacement amino acid.  At 
the time of that study, it was unclear whether “irreversible binding” was due to tightness of 
binding to the receptor or proficiency of insertion into the membrane. Our binding studies of the 
mutant protein 1Ab-F371C and the double mutant protein 1Ab-F371A/V171C to cadherin 
receptor (Dorsch TBR sequence of repeats 11 and 12 (26)) using surface plasmon resonance 
support the view that these mutants do not suffer significant loss in binding to M. sexta cadherin 
when compared to the wild type protein. However, the data from toxicity bioassays and the 
voltage clamping studies reflect the inability of the mutant forms to retain their toxicity or ion 
Figure 3: Voltage clamp response of Cry1Ab wt () compared to that of BBMV- inserting 
mutant V171C () and BBMV non-inserting mutants F371C (▼) and V171C/F371A ()  
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channel activity. This indicates a role for the residue F371 in associations of the toxin with the 
BBMV post receptor-binding in membrane insertion. Steady state fluorescence measurements of 
the bound and protected toxin show a blue shift in the maximal wavelength of the domain I 
mutant protein, suggesting the displacement of the label to a hydrophobic (membrane) 
environment (24). The hydrophobicity could hypothetically be due to binding of toxin to receptor 
(assuming the receptor is sufficiently hydrophobic), however, since binding is not greatly 
affected, this seems unlikely. In addition, one would expect proteinase K treatment would be 
able to access and digest the region of the receptor exposed outside the membrane and thereby 
also digest the toxin, given the incubation conditions of 30 min. Furthermore, when V171C, a 
domain I residue that is not believed to make contact with the receptor is labeled with acrylodan, 
we observe that the label migrates to a more hydrophobic environment in BBMV (Figure 2A). 
Our data from the proteinase K for the domain I mutant protein 1AbV171C and other mutants 
(manuscript in progress) dispersed across the toxin confirm that the label is in an environment 
not accessible by the protease suggesting that it is embedded into the bilayer. However, when the 
label is attached to the cysteine on position 371, the toxin was unable to enter the vesicles, 
leaving the protein exposed to proteinase K even after binding to the receptors on BBMV. This is 
also the case for the double mutant where the fluorescent label is on domain I residue but also 
incorporates a mutation in position 371 in domain II. Non receptor-mediated residual partitioning 
of the regions of domain I (around position 171) into the vesicles occurs in BBMV explaining 
the residual fluorescence associated with the proteinase K treated BBMV, in the case of double 
mutant 1Ab-F371A/V171C. SDS PAGE gels show a 60 kDa protected form of toxin for the wild 
type and 1AbV171C (Figure 1), which is also seen in case of several other mutations in 1Ab 
toxin (Figure 4). But an absence of that form for the F371C or F371A double mutant  
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corroborates the pattern of fluorescence data.  
 
 
An interesting observation in these studies is that Cry1Ab membrane partitioning into 
BBMV is different than its partitioning into SUV.  Labeling the toxin on -helix 5 of domain I 
(residue 171) with acrylodan showed a blue shift in both BBMV and SUV when domain II 
residue 371 is wild-type (Phe). When residue 371 is mutated to alanine the acrylodan-labeled 
domain I undergoes a blue shift in SUV and is protected from proteinase K, but not in BBMV. 
This indicates that domain I, at least residue 171 or -helix 5, is able to enter the artificial SUV 
membrane but not the BBMV membrane, even if residue 371 is alanine or cysteine. 
 The larger goal of this study is to determine the mechanism of insertion of the toxin. The 
ability of domain II mutant to partition into the membranes of these vesicles is in agreement with 
the hypothesis proposed in our recent paper (27) that while -helices from domain I are able to 
 
 
     1     2    3             4     5      6 
Figure 4: Proteinase K protection assay of mutants in 3 domains of Cry toxin. Mutations 1Ab 
S176C (Domain I), 1Ab S443C (Domain II) and 1Ab F461C (Domain III) were expressed and 
purified (Lanes 1, 2 and 3) respectively. Proteinase K protection assay was performed and 
SDS-PAGE showing a 60 kDa protected form is observed for 1Ab S176C (Lane 4), 1Ab 
S443C (Lane 5) and 1Ab F461C (lane 6). 
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insert, the mechanism of insertion is not based solely on individual helices entering the 
membrane. Other studies (13) suggest a buried “unchanged structure” model for the toxin where 
almost all of the toxin is buried into the membrane. Our data support the view that the mode of 
entry of the toxin into the membrane is in the form of an intact 60 kDa monomer or oligomeric 
toxin that lacks -helix 1 at its N-terminus. 
 
EXPERIMENTAL PROCEDURES 
Site-directed mutagenesis. Uracil-containing template of Cry1Ab was obtained as described (17). Site-
directed mutagenesis was carried out using the MutaGene M13 In Vitro Mutagenesis kit as described in 
the manufacturer’s manual (BioRad). The presence of the expected mutations in Cry1Ab (V171C, F371C 
and the double mutant: V171C/F371A) were confirmed by sequencing double-stranded DNA at the Plant 
Microbe Genomics Facility, Ohio State University, Columbus, Ohio. Expression and purification of the 
Cry1Ab wild-type and mutant toxins were carried out as described elsewhere (18). Secondary structure of 
each mutant was confirmed using circular dichroism spectrophotometry. 
Preparation of small unilamellar vesicles. 1-Palmitoyl-2-oleyl-sn-glycerol-3-phophatidylcholine, 1-
Palmitoyl-2-oleyl-sn-glycerol-3-phosphatidylethanolamine and cholesterol (Avanti Polar lipids Inc.) were 
used in the ratio of 7:2:1 to prepare small unilamelar vesicles (SUV) using a Branson Sonifier water bath. 
The protocol is described elsewhere (19). 
Preparation of BBMV. Fifth instar larvae of M.sexta were dissected as described elsewhere (20). BBMV 
were prepared by modified differential magnesium precipitation method (21). The final BBMV pellet was 
resuspended in binding buffer (10 mM HEPES, 150 mM NaCl pH 7.4).  Protein concentration was 
estimated using Coomassie Protein Assay reagent (Pierce Biotechnologies, Inc.) 
Proteinase K protection assays. Protection assays were performed as described using a protocol described 
elsewhere (12). Western blots of the protected sample were done using anti-Cry1A polyclonal antibody 
(1:5000) 
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Labeling of purified cysteine mutant toxins. Purified cysteine mutants were mixed with 10-fold molar 
excess of 6-acryloyl-2-dimethylaminonapthalene (Acrylodan) (Invitrogen Inc.) and incubated in the dark 
overnight. The labeled protein was purified off the free label using desalting Sephadex G25 column (GE 
Healthcare). Purity of the labeled protein was checked on an 8% SDS-PAGE gel and the degree of 
labeling was estimated using the molar extinction coefficient of acrylodan. 50 g of the labeled protein 
was mixed with 500 g BBMV or 5 mgs of SUV and incubated for 60 min. Bound forms of the labeled 
protein were separated from the unbound labeled proteins by either centrifuging the BBMV pellet down 
at 15000 g or by passing the SUVs through a Sephadex G100 column (GE Healthcare). The BBMV or 
SUV was treated with 500 g of proteinase K and incubated for 30 min at 37o C. 1 mM PMSF was added 
to stop the reaction. The reaction was then spun down at 15000 g to recover the BBMV or passed through 
Sephadex G 100 column (GE Healthcare) to recover the SUV.  
Fluorescence measurements. Steady state fluorescence measurements were carried out on Fluoromax 3 
fluorimeter (JY Horiba Instruments). The labeled proteins were excited at 360 nm and emission intensity 
was measured from 390- 600 nm. The labeled protein in solution, bound to BBMV and proteinase K 
treated were measured simultaneously to avoid any instrumentation error. Spectra were corrected for 
background from buffer and /or the vesicles. Each experiment was performed three times. Emission 
spectra were plotted using relative fluorescence of the mutants in buffer to that in the membrane before 
and after proteinase K treatment.  
Surface plasmon resonance analysis. Surface plasmon resonance experiments on BIAcore 3000 were 
performed for kinetic analysis. BIAcore’s carboxymethylated dextran matrix (CM5) sensor chip was 
used. The analysis temperature was set to 25
o 
C. Around 15000 RU of anti-MBP IgG was immobilized on 
the surface of flow cell 2 on the CM5 sensor chip using an EDC/NHS-mediated amine coupling 
procedure. A freshly prepared solution of 50 mM NHS (N-hydroxysuccinimide) and 0.2M EDC [1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide] was injected for 7 min to activate the flow cell. Anti-MBP IgG 
was reconstituted in 10 mM NaCOOH, pH 5.0 and injected at a flow rate of 10 l/min. Excess activated 
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ester groups on the surface were deactivated using a 7 minute injection of 1 M ethanolamine-HCl, pH 8.5. 
Flow cell 1 was activated with 50 mM NHS and 0.2 M EDC and blocked with 1M ethanolamine-HCl, pH 
8.5 without immobilization of anti-MBP IgG, serving as the reference surface. 
 Maltose binding protein-receptor fusion protein, MBP-CAD-D was constructed as a subclone of 
the M. sexta CAD gene provided to us in pMECA vector (22) including CAD regions 11 and 12. MBP-
CAD-D at 50 g/ml was injected at a flow rate of 5l/min to interact with IgG on the chip. Over a 3 min 
period of time, approximately 100 RU of MBP-receptor was captured. The (anti-MBP IgG)-(MBP-CAD-
D) surface was allowed to stabilize for 1 min, before wild type toxin at various concentrations were 
injected. Buffer only was included as a blank. The flow rate for toxin injections was at 30 l/min. The 
association phase was 3 min and the dissociation phase was 10 min. Regeneration was achieved by two 
30-second injections of 10 mM glycine, pH 1.8 at 100 l/min. The control flow cell that was activated 
and blocked without immobilization of the antibody had both MBP-receptor fusion protein and toxin 
flowing through in each cycle. Running buffer in all experiments was HBS-P buffer (0.01 M HEPES, pH 
7.4, 0.15 M NaCl, 0.005% surfactant). MBP-CAD-D fusion protein was purified in the same buffer, while 
toxin was prepared in sodium carbonate buffer and filter-dialyzed into the HBS-P buffer. 
Toxicity Bioassays. Toxicity levels were determined on first instar M. sexta larvae. The median lethal 
concentration (LC50) was estimated by diet surface contamination assays as described (18). 
Voltage clamp analysis. Voltage clamp analysis was performed as described earlier (20).After 
stabilization of the midguts in the buffer (23), 100 ng of each toxin was added to the lumen side of the 
chamber. The volume of the lumen chamber is 3.75ml. Recorded data was normalized to the percentage 
of Isc remaining. Each experiment was repeated at least 3 times.  
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